https://magnosco.com
Magnosco is a MedTech company specializing in the development of innovative solutions for the early detection of skin cancer. The company was founded in 2014 in Berlin, Germany.
Magnosco develops AI-powered analysis tools and medical devices such as the Magnosco DermaFC, which is used for the early detection of melanomas using non-invasive dermatofluoroscopy. The method is painless and has been awarded CE certification for the European market as a Class IIa medical device[5][7]. The Magnos-App enables the efficient management and communication of dermatoscopic images, which improves diagnostic processes[1].
The mission of Magnosco is to improve access to precise dermatological diagnoses and promote the early detection of skin cancer. By combining AI-powered analysis and medical research, the company aims to digitally supplement expertise in dermatology and make it more accessible to everyone[2][3]. The company's values emphasize user-friendly product development and progressive research to accelerate and refine diagnostic processes.
Although specific sustainability goals are not explicitly mentioned, Magnosco focuses on improving the diagnosis of skin cancer, which leads to better treatment opportunities and an increased quality of life for patients. This can be seen as an important contribution to improving healthcare[5]. In addition, the company is working on further developing its technologies to standardize and broaden the application of skin cancer early detection methods.
Magnosco conducts intensive research and development work to continuously improve its technologies. A clinical study has already demonstrated initial successes: AI-supported diagnoses resulted in more correct findings than traditional methods without AI[3]. Further studies are planned to substantiate the effectiveness of the methods.
Magnosco has successfully completed several rounds of financing and was acquired by LTB Holding in 2022. Today, the company is managed by Thomas Diepold and Dr. Sebastian Ahlberg[3].
